خبر جيد
Associated Press
Cerus, Baxter Intend Larger BioOne Deal
Wednesday January 5, 11:10 am ET
Cerus, Baxter Intend to Expand BioOne Intercept Blood System for Plasma Products in Asia
CONCORD, Calif. (AP) -- Cerus Corp. reported Wednesday that it and units of health-care products company Baxter International Inc. agreed to allow BioOne Corp. to commercialize their Intercept blood system for plasma products in Asia.
Cerus, which co-developed Intercept with marketing partner Baxter, received an upfront payment of $3 million for signing a letter of intent. The companies are in talks for a definitive agreement.
Cerus and Baxter received $15 million in October from BioOne to commercialize the pathogen inactivation technology in Japan, China, Taiwan, South Korea, Thailand, Vietnam and Singapore for platelet products. The new agreement covers plasma products in the same countries.
Shares of Cerus rose 2 cents to $3.33 in morning trading on the Nasdaq. Baxter shares rose 69 cents, or 2 percent, to $35.24 on the New York Stock Exchange.
بالتوفيق